Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xechem International has received orphan drug designation from the FDA for its investigational compound, 5-HMF, for the treatment of patients suffering from sickle cell disease - an inherited disorder that can create clogs in blood vessels.
Subscribe to our email newsletter
Orphan drug status, given to drugs intended to treat diseases afflicting less than 200,000 people in the US, will entitle Xechem to various incentives, including the waiving of regulatory filing fees, access to potential grant funding for non-clinical and clinical research to generate required data for marketing approval, and seven years of marketing exclusivity for 5-HMF if approved by the FDA.
According to the company, 5-HMF is a natural product with very little, if any, toxicity, and a high affinity for sickle cell hemoglobin.
“We are pleased with the FDA's decision granting orphan drug designation to 5-HMF. This puts Xechem into a unique position where the company will have two drugs in the pipeline for treating patients with sickle cell disease,” said Dr Ramesh Pandey, CEO of Xechem.
“5-HMF is a new type of drug that interacts specifically with intracellular hemoglobin without interacting with other proteins in the body. Today there are no non-toxic drugs available on the market to treat SCD,” Dr Pandey continued.